文献类型：期刊文献

英文题名：Therapeutic mechanism of Jinshui Liujunzi Decoction in treating COPD: targeting the PI3K/Akt signaling pathway

作者：Wang, Zhiwang[1];Liang, Keke[1];Zhao, Yue[1];Huang, Keting[1];Li, Yun[1]

第一作者：王志旺

通信作者：Wang, ZW[1]

机构：[1]Gansu Univ Chinese Med, Coll Pharm, Lanzhou 730000, Peoples R China

第一机构：甘肃中医药大学药学院（西北中藏药协同创新中心办公室）

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Coll Pharm, Lanzhou 730000, Peoples R China.|[1073501e14fb35863569f]甘肃中医药大学药学院（西北中藏药协同创新中心办公室）;[10735]甘肃中医药大学;

年份：2025

卷号：351

外文期刊名：JOURNAL OF ETHNOPHARMACOLOGY

收录：;Scopus(收录号：2-s2.0-105007335140);WOS:【SCI-EXPANDED(收录号:WOS:001507011300001)】；

基金：This study was supported by the National Natural Science Founda-tion of China (Grant numbers: 82260852, 81460668) and the Outstanding Doctoral Student Project of Gansu Province (Grant number: 25JRRA258) .

语种：英文

外文关键词：Network pharmacology; Molecular docking; COPD; Jinshui Liujunzi Decoction; PI3K; Akt

摘要：Ethnopharmacological relevance: Jinshui Liujunzi decoction (JZD) has been widely used in the treatment of chronic obstructive pulmonary disease (COPD), and has good antioxidant and anti-inflammatory effects, but its specific active ingredients and mechanism of action are still unclear. The purpose of the study: To elucidate the molecular mechanisms of JZD in treating COPD and experimentally validate its efficacy. Methods: Network pharmacology was used to identify the active components of JZD and molecular targets of COPD. A herb-component-target-disease network was constructed, and the binding energy between JZD's active components and targets was validated through molecular docking. A COPD animal model was established by repeated intranasal instillation of cigarette smoke extract containing lipopolysaccharide (LPS). Mice were administered low-, medium-, and high-dose JZD (4.8 g/kg, 9.6 g/kg, and 19.2 g/kg) daily by gavage. Behavioral changes, lung function, lung index, lung wet/dry weight ratio, and lung tissue pathology were observed. The total number of inflammatory cells, neutrophils, and macrophages in bronchoalveolar lavage fluid (BALF) was counted. ELISA was used to measure IL-1 beta, IL-4, and IL-13 levels in BALF, PCR was used to determine the relative expression of PI3K and Akt genes, and Western blot was used to measure PI3K and Akt protein expression levels. Results: Network pharmacology analysis identified 267 active components of JZD, corresponding to 608 targets. A total of 6570 COPD-related targets were obtained from five databases (GeneCards, OMIM, PharmGKB, TTD, and DrugBank), with 476 overlapping targets. KEGG analysis revealed that JZD primarily acts on the PI3K/Akt signaling pathway in COPD treatment. Molecular docking results showed that the binding energy between JZD's key components and core targets was less than -5.0 kcal/mol, with PIK3R1 exhibiting the strongest binding affinity. In the COPD mouse model, JZD significantly improved behavioral outcomes, increased peak expiratory flow (PEF), tidal volume (TV), and body weight, and reduced lung weight, lung index, and lung wet/dry weight ratio. JZD also alleviated pathological changes in lung tissue, reduced inflammatory cell infiltration in the bronchi, and decreased the levels of inflammatory cells, neutrophils, macrophages, IL-1 beta, IL-4, and IL-13 in BALF. Furthermore, JZD downregulated the expression of PI3K, Akt, and their genes in lung tissue. Conclusion: JZD exhibits significant therapeutic effects on COPD, likely mediated through the inhibition of the PI3K/Akt signaling pathway.